Treatment of seizures in the neurologic intensive care unit

Artifact: recording EEG in special care units

Artifacts may be obtained during routine recording but are more common in special care units (SCUs) outside of the EEG laboratory, where complex electrical currents are present that create a "hostile" environment. Special care units include the epilepsy monitoring unit, neurologic intensive care unit, and operating room, where artifact is present in virtually every recording, increasing with prolonged use. Nonepileptic attacks treated as epileptic seizures have been incorrectly diagnosed and treated due to a misinterpreted EEG. The recent emergence of continuous EEG as a neurophysiologic surrogate for brain function in the neurologic intensive care unit and operating room has also brought a greater amount and new types of EEG artifact. The artifacts encountered in special care units during continuous EEG are becoming more complex and may have adverse therapeutic implications. Our knowledge of artifact needs to parallel our growth in technology to avoid the pitfalls that may be incurred during visual analysis of the EEG.

Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage

OBJECTIVE

Both valproic acid and levetiracetam are anti-epileptic drugs, often used either alone or in combination. The present study compares valproate (VPA) with levetiracetam (LEV) as an intravenous (i.v.) anticonvulsant treatment in intensive care patients suffering from aneurysmal subarachnoid hemorrhage (aSAH) with a high risk of seizures.

PATIENTS AND METHODS

A prospective, single-center patient registry of 35 intensive care unit (ICU) patients with onset seizure and/or high risk of seizures underwent an anticonvulsive, first-line single treatment regimen either with VPA or LEV. Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded.

RESULTS

A significant decrease in the pc in patients treated with LEV was observed after changing from intravenous (160±51μmol/l) to enteral liquid application (113±58μmol/l), corresponding to a 70.3% bioavailability for enteral liquid applications. The pc in VPA patients decreased significantly, from (491±138μmol/l) to (141±50μmol/l), after adding meropenem to the therapy (p<0.05). Three epileptic seizures occurred during anticonvulsive therapy in the LEV group, and two in the VPA group, including one non-convulsive status epilepticus (NCSE).

CONCLUSION

Though this finding needs further verification, the enteral liquid application of levetiracetam seems to be associated with lower bioavailability than the common oral application of levetiracetam. The use of the antibiotic drug meropenem together with valproic acid leads to lower pc levels in patients treated with of valproic acid. For clinical practice, this indicates the need to monitor the levels of valproic acid in combination with meropenem.

Seizures and status epilepticus in the critically ill

Seizures represent stereotypic electroencephalographic (EEG) and behavioral paroxysms as a consequence of electrical neurologic derangement. Seizures are usually described as focal or generalized motor convulsions; however, nonconvulsive seizures that occur in the absence of motor activity may escape clinical detection. Because of the admission diagnoses and dramatic physiologic and metabolic derangements common to critically ill patients, the entire spectrum of seizure disorders may be encountered in the ICU. Seizures in the ICU are attributable to primary neurologic pathology or secondary to critical illness and clinical management. For optimal treatment, early diagnosis of the seizure type and its cause is important to ensure appropriate therapy. Convulsive status epilepticus requires emergent treatment before irreversible brain injury and severe metabolic disturbances occur.